However biallelic mutation of ATM and TP53 result in reduction in CLL engraftment in vivo suggesting that mutual targeting of both ATM and TP53 is favorable in aberrating CLL. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.